{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T07:42:30Z","timestamp":1713339750412},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T00:00:00Z","timestamp":1363564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients are commonly prescribed several medications and are thus at risk for drug interactions that may result in <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation. We sought (1) to identify the frequency of electrocardiogram (<jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content>) monitoring (2), to determine the prevalence of drug interactions involving <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content>\u2010prolonging medications, and (3) to quantify the prevalence of <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional study was conducted among <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected adults. Demographics, medications, drug interactions and comorbidities were abstracted from patients' medical records. Abnormal <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval was defined per the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> Committee for Proprietary Medicinal Products. Clinical characteristics were compared among <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> recipients and nonrecipients. Among <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> recipients, the prevalence and predictors of <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 454 patients included in the study, 80.8% were prescribed a medication associated with <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation and 39% had drug interactions expected to increase <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation risk. There were 138 patients (30.3%) who received <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> testing. Receipt of <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> monitoring was associated with increasing age, diabetes, increasing total number of medications and gastroesophageal reflux disease. Among <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> recipients, the prevalence of abnormal <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval was 27.5%. Chronic kidney disease [prevalence ratio (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) 3.47; 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 1.37\u20138.83; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.009], hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus coinfection (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> 2.26; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.97\u20135.27; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.06) and hypertension (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> 2.11; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.93\u20134.81; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.07) were independently associated with an abnormal <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A low frequency of <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> testing was observed, despite a high use of medications associated with <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> prolongation. The risk of abnormal <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval was highest among patients with chronic kidney disease, hypertension and hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus coinfection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12031","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T05:38:37Z","timestamp":1363671517000},"page":"463-471","source":"Crossref","is-referenced-by-count":9,"title":["Frequency of electrocardiogram testing among <scp>HIV<\/scp>\u2010infected patients at risk for medication\u2010induced <scp>QTc<\/scp> prolongation"],"prefix":"10.1111","volume":"14","author":[{"given":"N","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences  Albany NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Veve","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences  Albany NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of HIV Medicine Albany Medical College  Albany NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u2010A","family":"McNutt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health University at Albany State University of New York  Rensselaer NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Fish","sequence":"additional","affiliation":[{"name":"Division of HIV Medicine Albany Medical College  Albany NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CD","family":"Miller","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy and Medicine Upstate Medical University  Syracuse NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,18]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr248"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03948.x"},{"key":"e_1_2_5_4_1","first-page":"672","article-title":"Registry for torsades de pointes with drug treatment exists","volume":"322","author":"Kilborn MJ","year":"2001","journal-title":"BMJ"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7243.1158"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0293-5"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/511875"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011400071"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90824-1"},{"key":"e_1_2_5_11_1","first-page":"53","article-title":"QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim\u2010sulfamethoxazole administration","volume":"48","author":"Wiener I","year":"1981","journal-title":"Mt Sinai J Med."},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10210"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P576"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30135-4"},{"key":"e_1_2_5_15_1","first-page":"53","article-title":"Drug\u2010induced QT prolongation and sudden death","volume":"107","author":"Del Rosario ME","year":"2010","journal-title":"Mo Med"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"K70","DOI":"10.1016\/S1520-765X(01)90009-4","article-title":"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes","volume":"3","author":"Dapro B","year":"2001","journal-title":"Eur Heart J"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03357.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607253350416"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500120070028"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00083.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.7.684"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03660.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03332.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1004-261"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.11.001"},{"key":"e_1_2_5_26_1","first-page":"1657","article-title":"Tc interval prolongation in patients with HIV and AIDS","volume":"97","author":"Sani MU","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"e_1_2_5_27_1","unstructured":"HaahrM.Random.org\u2010list randomizer. Dublin.1998. Available atwww.random.org(accessed 10 January 2011)."},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"e_1_2_5_29_1","first-page":"104","article-title":"Atazanavir: new indication. First\u2010line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"e_1_2_5_30_1","first-page":"17","article-title":"Saquinavir: prolongation of PR and QT intervals","volume":"20","year":"2011","journal-title":"Prescrire Int"},{"key":"e_1_2_5_31_1","volume-title":"Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non\u2010cardiovascular Medicinal Products","author":"Committee for Proprietary Medicinal Products","year":"1997"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg074"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/278427"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328341dcc0"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.10.1379"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2005.09.001"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12031","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:43:34Z","timestamp":1696315414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,18]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/hiv.12031"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12031","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,18]]}}}